Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Co. Ltd (OP: ESALF )

41.68 +1.68 (+4.20%)
Streaming Delayed Price Updated: 12:59 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Co. Ltd

< Previous 1 2 3 Next >
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Via Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that... 
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Via Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Via Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
Via Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Via Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
The  
Via Benzinga
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically... 
Via Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for... 
Via Benzinga
Why Are Biogen Shares Gaining Today?
​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:... 
Via Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across... 
Via Benzinga
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab... 
Via Benzinga
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-... 
Via Benzinga
Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free
Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ... 
Via Benzinga
White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people... 
Via Benzinga
Exposures Product Safety
Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's
Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300... 
Via Benzinga
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:... 
Via Benzinga
Know When To Hold 'Em, Know When To Fold 'Em ...
A long Monday list identifying some sensible and some impenetrable moves behind today's market in our stocks. 
Via Talk Markets
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ... 
Via Benzinga
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ... 
Via Benzinga
Exposures Product Safety
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.